Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Eli Lilly (LLY) was in the limelight in pre-market trading on Thursday, after the pharmaceutical giant reported positive topline results from two late-stage clinical trials of its investigational obesity drug Retatrutide, strengthening its position in the rapidly growing weight-loss market as competition with Novo Nordisk (NVO) intensifies
Great during travel season or when you feel a cold coming on
PlexusDx clinicians use these insights to recommend the most cost-effective and clinically matched treatment pathway, ensuring maximum weight-loss results per dollar invested
10.1212/WNL.0000000000209928 Neurology 14 BercikP.ParkA
Subtype-specific scores were computed for each (untreated) sample via single-sample gene set enrichment analysis (ssGSEA), implemented through the clusterProfiler package
As a provider, if you can prescribe a single, once-a-week treatment that improves a patients metabolism, mental health, heart health, and blood pressure while reducing addictive drive and mortality, that is an extremely appealing option with high adherence potential
US$ 24.88
US$ 21.21
US$ 29.05
US$ 29.54
US$ 28.50
